Global Parkinsons Disease Drugs Market 2018-2024

Global Parkinson’s Disease Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024

Overview:
Parkinson’s disease is one of the most prevalent neurodegenerative disorders, which progresses with age because of damaged dopaminergic cells in the brain. Bradykinesia, rigidity, postural instability, and tremors are the symptoms of the Parkinson’s disease. Huge patient pool and rising rate of diagnosis are the significant factors driving the market growth. The Parkinson’s Disease Foundation has stated that nearly 10 million people are suffering from this disorder globally. The highest frequency of this disorder is observed in developed countries, and in the US, almost 60,000 new cases are reported annually.

PD is an idiopathic disease for which the cause of the occurrence is still unknown, hence only symptomatic drugs are available in the market for the treatment. Furthermore, the disorder is diagnosed in the final stages when the majority of the cells that produce dopamine lose their functionality. This is demanding more innovative and novel drugs for the treatment.

Market Analysis:
The “Global Parkinson’s Disease Drugs Market” is estimated to witness a CAGR of 7.2% during the forecast period 2018–2024. The market is analyzed based on two segments – drug class and regions.

Regional Analysis:
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America accounts for the largest share of the market, followed by Europe, Asia Pacific, and Rest of the World. More than 40% of the market is occupied by Europe, with Germany being the major contributor to the market growth.

Drug Class Analysis:
Based on drug classes, the market is segmented into levodopa, MAO-B inhibitors, COMT inhibitors, dopamine agonists, anticholinergics, and others. Levodopa is the most attractive drug in the market owing to its highly effective treatment in controlling the motor symptoms throughout the stages of Parkinson’s disease. Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa. This is the original drug indicated explicitly for dyskinesia, which is technologically advanced with the long-term use of levodopa.

Key Players:
The major players in the market include Novartis, Roche, AbbVie, Teva Pharmaceutical, Pfizer, STADA Arzneimittel AG, GSK, Valeant, Merck & Co. Inc., and Amneal Pharmaceuticals Inc.

Competitive Analysis:
New product launch and collaboration are the primary strategies being followed by the market players to maintain their leadership and strengthen the market position. In January 2015, Neuropore Therapies Inc. and UCB S.A. signed a commercialization agreement for NPT200-11. Recently, Impax Pharmaceuticals’ RYTARY and AbbVie’s DUOPA received the US FDA approval for the treatment of Parkinson’s disease. Other strategies include business partnerships, mergers & acquisitions, and a multifaceted pipeline. Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa.

Benefits:
The report provides complete details about the usage and adoption rate of Parkinson’s disease drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

1 Industry Outlook 9
1.1 Industry Overview 9
1.1.1 Global Driver for Pharmaceutical Demand: 10
1.1.2 Pharmaceutical spending region wise 10
1.1.3 R&D pipeline in pharmaceutical industry 10
1.1.4 Top pharma drugs by sales in 2017 ($Million) 12
1.2 Total Addressable Market 13
2 Report Outline 15
2.1 Report Scope 15
2.2 Report Summary 15
2.3 Research Methodology 16
2.4 Report Assumptions 16
3 Market Snapshot 18
3.1 Market Definition – Infoholic Research 18
3.2 Segmented Addressable Market (SAM) 18
3.3 Trends of Parkinson Diseases Market 19
3.4 Related Markets 20
3.4.1 Neurosurgical Devices 20
3.4.2 Neurointerventional Devices 21
3.4.3 Over the counter drugs (OTC) 23
4 Market Outline 25
4.1 Pipeline Products of Parkinson Diseases Drugs 25
4.2 Market Segmentation 30
4.3 Porter 5(Five) Forces 31
4.4 PEST Analysis 32
5 Market Characteristics 33
5.1 Market Dynamics of Parkinson Diseases Market 33
5.1.1 Drivers 34
5.1.1.1 Increasing Aging Population 34
5.1.1.2 Increasing Prevalence of Parkinson Diseases 34
5.1.2 Opportunities 36
5.1.2.1 Supportive initiatives from government and other organizations 36
5.1.2.2 Exhaustive Pipeline and Increasing Clinical Trials 37
5.1.3 Restraints 37
5.1.3.1 Expiry of patents for blockbuster drugs and availability of generic drugs 37
5.1.3.2 Complex drug development process 38
5.1.4 DRO – Impact Analysis 38
5.1.5 Key Stakeholders 39
6 Drug Type: Market Size and Analysis 40
6.1 Overview 40
6.2 Levodopa 41
6.3 Dopamine agonists 42
6.4 MAO-B inhibitors 43
6.5 COMT Inhibitor 44
6.6 Anticholinergics 45
6.7 Others 46
7 Regions: Market Size and Analysis 48
7.1 Overview 48
7.2 North America 50
7.2.1 Overview 50
7.3 Europe 51
7.3.1 Overview 51
7.4 APAC 53
7.4.1 Overview 53
7.5 Rest of the World 54
7.5.1 Overview 54
8 Competitive Landscape 56
9 Vendor Profiles 58
9.1 Novartis AG 58
9.1.1 Overview 58
9.1.2 Business Unit 62
9.1.3 Geographic Presence 63
9.1.4 Business Focus 64
9.1.5 SWOT Analysis 64
9.1.6 Business Strategy 65
9.2 GlaxoSmithKline plc 66
9.2.1 Overview 66
9.2.2 Geographic Presence 70
9.2.3 Business Focus 70
9.2.4 SWOT Analysis 71
9.2.5 Business Strategy 71
9.3 F.Hoffmann-La Roche Ltd. 72
9.3.1 Overview 72
9.3.2 Business Unit 75
9.3.3 Geographic Presence 76
9.3.4 Business Focus 77
9.3.5 SWOT Analysis 77
9.3.6 Business Strategy 78
9.4 AbbVie Inc. 78
9.4.1 Overview 78
9.4.2 Geographic Presence 81
9.4.3 Business Focus 81
9.4.4 SWOT Analysis 82
9.4.5 Business Strategies 82
9.5 Merck & Co., Inc. 83
9.5.1 Overview 83
9.5.2 Business units 84
9.5.1 Geographic Revenue 85
9.5.2 Business focus 86
9.5.3 SWOT analysis 86
9.5.4 Business strategies 87
9.6 Teva Pharmaceutical Industries Ltd. 88
9.6.1 Overview 88
9.6.2 Business Unit 90
9.6.3 Geographic Presence 91
9.6.4 Business focus 92
9.6.5 SWOT analysis 92
9.6.6 Business Strategy 93
9.7 Valeant Pharmaceuticals International Inc. 93
9.7.1 Overview 93
9.7.2 Business Unit 96
9.7.3 Geographic Presence 97
9.7.4 Business Focus 97
9.7.5 SWOT Analysis 97
9.7.6 Business Strategy 98
10 Companies to Watch For 99
10.1 Boehringer Ingelheim GmbH 99
10.1.1 Overview 99
10.1.2 Highlights 99
10.2 Amneal Pharmaceuticals, Inc. 101
10.2.1 Overview 101
10.3 Wockhardt 102
10.3.1 Overview 102
10.3.2 Highlights: 102
10.4 STADA Arzneimittel AG 102
10.4.1 Overview 102
10.4.2 Highlights 103
10.5 Pfizer Inc. 104
10.5.1 Overview 104
10.5.2 Highlights 105
10.6 Sun Pharmaceuticals 106
10.6.1 Overview 106
10.6.2 Highlights 107
Annexure 108
Abbreviations 108
 


List Of Tables

TABLE 1 CLINICAL TRIALS OF NEUROINTERVENTIONAL DEVICES 23
TABLE 2 PARKINSON DISEASES DRUGS: PIPELINE PRODUCTS 25
TABLE 3 PATENT EXPIRATION OF PARKINSON DISEASE DRUGS 37
TABLE 4 PARKINSON DISEASES MARKET REVENUE BY DRUG TYPE, 2017–2024 ($MILLION) 40
TABLE 5 PARKINSON DISEASES MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 49
TABLE 6 NOVARTIS AG: OFFERINGS 58
TABLE 7 NOVARTIS AG: RECENT DEVELOPMENTS 59
TABLE 8 GLAXOSMITHKLINE PLC: OFFERINGS 66
TABLE 9 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 67
TABLE 10 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS 72
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 73
TABLE 12 ABBVIE INC.: OFFERINGS 78
TABLE 13 ABBVIE INC: RECENT DEVELOPMENTS 78
TABLE 1 MERCK & CO: PRODUCT OFFERINGS 83
TABLE 2 MERCK & CO: RECENT DEVELOPMENTS 83
TABLE 3 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 88
TABLE 4 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 88
TABLE 5 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS 93
TABLE 6 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS 94
TABLE 7 BOEHRINGER INGELHEIM GMBH: OVERVIEW 99
TABLE 8 BOEHRINGER INGELHEIM: RECENT DEVELOPMENTS 100
TABLE 9 AMNEAL PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW 101
TABLE 10 AMNEAL PHARMACEUTICAL: RECENT DEVELOPMENTS 101
TABLE 11 WOCKHARDT.: OVERVIEW 102
TABLE 12 STADA ARZNEIMITTEL AG: OVERVIEW 102
TABLE 13 STADA ARZNEIMITTEL AG: RECENT DEVELOPMENTS 103
TABLE 14 PFIZER INC. OVERVIEW 104
TABLE 15 PFIZER INC.: RECENT DEVELOPMENTS 104
TABLE 16 SUN PHARMACEUTICALS: OVERVIEW 106
TABLE 17 SUN PHARMACEUTICALS: RECENT DEVELOPMENTS 106
 


List Of Figures

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 10
CHART 2 R&D INVESTMENT BY TOP 10 COMPANIES ($BN) 11
CHART 3 RESEARCH METHODOLOGY OF GLOBAL PARKINSONS DISEASES MARKET 16
CHART 4 GLOBAL PARKINSON DISEASE MARKET REVENUE, 2017-2024 ($MILLION) 19
CHART 5 SEGMENTATION OF GLOBAL PARKINSON DISEASES DRUGS MARKET 30
CHART 6 PORTER 5 FORCES OF PARKINSON DISEASES MARKET 31
CHART 7 PEST ANALYSIS OF PARKINSON DISEASES MARKET 32
CHART 8 MARKET DYNAMICS – DRO ANALYSIS 33
CHART 9 DRO – IMPACT ANALYSIS OF GLOBAL PARKINSON DISEASES MARKET 38
CHART 10 KEY STAKEHOLDERS 39
CHART 11 PARKINSON DISEASE MARKET BY DRUG TYPE, 2017 VS 2024 (%) 40
CHART 12 LEVADOPA DRUGS MARKET REVENUE, 2017-2024 ($MILLION) 41
CHART 13 DOPAMINE AGONIST MARKET REVENUE, 2017-2024 ($MILLION) 42
CHART 14 MAO-B MARKET REVENUE, 2017-2024 ($MILLION) 43
CHART 15 COMT INHIBITORS MARKET REVENUE, 2017-2024 ($MILLION) 44
CHART 16 ANTICHOLINERGICS MARKET REVENUE, 2017-2024 ($MILLION) 45
CHART 17 OTHER DRUGS MARKET REVENUE, 2017-2024 ($MILLION) 46
CHART 18 PARKINSON DISEASES MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 49
CHART 19 PARKINSON DISEASES MARKET REVENUE IN THE NORTH AMERICA REGION, 2017–2023 ($MILLION) 50
CHART 20 THE PREVALENCE RATE OF PD IN EUROPE 51
CHART 21 PARKINSON DISEASES MARKET REVENUE IN THE EUROPEAN REGION, 2017–2023 ($MILLION) 52
CHART 22 PARKINSON DISEASES MARKET REVENUE IN THE APAC REGION, 2017-2024 ($MILLION) 53
CHART 23 PARKINSON DISEASES MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION) 54
CHART 24 NOVARTIS AG: OVERVIEW SNAPSHOT 58
CHART 25 NOVARTIS AG: BUSINESS UNITS 62
CHART 26 NOVARTIS AG: GEOGRAPHICAL PRESENCE 63
CHART 27 NOVARTIS AG: SWOT ANALYSIS 64
CHART 28 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 66
CHART 29 GLAXOSMITHKLINE PLC: BUSINESS UNITS 69
CHART 30 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE 70
CHART 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 71
CHART 32 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 72
CHART 33 F. HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS 75
CHART 34 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE 76
CHART 35 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 77
CHART 36 ABBVIEE INC: OVERVIEW SNAPSHOT 80
CHART 37 ABBVIEE INC.: GEOGRAPHIC PRESENCE 81
CHART 38 ABBVIE INC.: SWOT ANALYSIS 82
CHART 39 MERCK & CO: OVERVIEW SNAPSHOT 84
CHART 40 MERCK & CO: BUSINESS UNITS 84
CHART 41 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 85
CHART 42 MERCK & CO: SWOT ANALYSIS 86
CHART 43 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT 89
CHART 44 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS 90
CHART 45 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE 91
CHART 46 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 92
CHART 47 VALEANT PHARMACEUTICALS INTERNATIONAL INC: OVERVIEW SNAPSHOT 94
CHART 48 VALEANT PHARMACEUTICALS INTERNATIONAL INC: BUSINESS UNITS 96
CHART 49 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL PRESENCE 97
CHART 50 VALEANT PHARMACEUTICALS INTERNATIONAL INC: SWOT ANALYSIS 97


Global Ultrasound Tumor Therapeutic Apparatus Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Ultrasound Tumor Therapeutic Apparatus is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by

USD 4000 View Report

Global Ultrasound probe Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Ultrasound probe is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end

USD 4000 View Report

North America Parkinsons Disease Drug Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The North America Parkinsons disease Drug market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD

USD 3000 View Report

Global Parkinsons Disease Drug Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Parkinsons disease Drug is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available